MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

Neurocrine Biosciences Inc

Slēgts

SektorsVeselības aprūpe

105.67 2.38

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

100.77

Max

105.77

Galvenie mērījumi

By Trading Economics

Ienākumi

-27M

103M

Pārdošana

5.6M

628M

P/E

Sektora vidējais

30.602

57.333

EPS

1.69

Peļņas marža

16.425

Darbinieki

1,800

EBITDA

-39M

152M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+46.61% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 5. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-5.1B

10B

Iepriekšējā atvēršanas cena

103.29

Iepriekšējā slēgšanas cena

105.67

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bullish Evidence

Neurocrine Biosciences Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 28. janv. 00:03 UTC

Karstas akcijas

Stocks to Watch: Graco, Brown & Brown, Neurocrine Biosciences

2025. g. 14. marts 09:30 UTC

Top Ziņas

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

2024. g. 13. aug. 11:30 UTC

Top Ziņas

S&P 500 Futures Climb In Premarket Trading; On Holding, Western Midstream Ptrs Lag

Salīdzinājums

Cenas izmaiņa

Neurocrine Biosciences Inc Prognoze

Cenas mērķis

By TipRanks

46.61% augšup

Prognoze 12 mēnešiem

Vidējais 155.05 USD  46.61%

Augstākais 185 USD

Zemākais 96 USD

Pamatojoties uz 20 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Neurocrine Biosciences Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

20 ratings

17

Pirkt

3

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

100.655 / 106.2Atbalsts un pretestība

Īstermiņā

Very Strong Bullish Evidence

Vidējā termiņā

Strong Bearish Evidence

Ilgtermiņā

Strong Bearish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL " Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.